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Abstract: The endolysosomal system (ES) consists of lysosomes; early, late, and recycling endosomes;
and autophagosomes. It is a key regulator not only of macromolecule degradation and recycling,
plasma membrane repair, homeostasis, and lipid storage, but also of antigen presentation, immune
defense, cell motility, cell death signaling, tumor growth, and cancer progression. In addition,
it plays a critical role in autophagy, and the autophagy-lysosome pathway is intimately associated
with the hallmarks of cancer, such as escaping cell death pathways, evading immune surveillance,
and deregulating metabolism. The function of endolysosomes is critically dependent on both soluble
and endolysosomal membrane proteins such as ion channels and transporters. Cation channels
found in the ES include members of the TRP (transient receptor potential) channel superfamily,
namely TRPML channels (mucolipins) as well as two-pore channels (TPCs). In recent studies, these
channels have been found to play crucial roles in endolysosomal trafficking, lysosomal exocytosis,
and autophagy. Mutation or loss of these channel proteins can impact multiple endolysosomal
trafficking pathways. A role for TPCs in cancer cell migration and metastasis, linked to distinct
defects in endolysosomal trafficking such as integrin trafficking, has been recently established. In this
review, we give an overview on the function of lysosomes in cancer with a particular focus on the
roles which TPCs and TRPML channels play in the ES and how this can affect cancer cells.
Keywords: calcium; TPC; two-pore; lysosome; TPC1; TPC2; TRPML; mucolipin; MCOLN; mTOR;
TRPML1; TFEB
1. Introduction
In Europe and the USA, cancer and cancer-related diseases account for about 25–30% of deaths.
Curative therapies are still the exception. Hence, there is an urgent need to find novel, innovative
targets and therapies and to develop new treatment strategies.
Targeting the lysosome has emerged as an increasingly attractive strategy in cancer therapy in
recent years [1–3]. That links exist between cancer and lysosomal function is not new. It has already
been postulated decades ago that an increased liberation of lysosomal hydrolases in tumors could
contribute to inflammatory and toxic effects and could promote the detachment of cells from tumor
masses and thus facilitate metastatic spread. In addition, several studies at the time had revealed
higher activities of different lysosomal enzymes in solid tumors than in their tissues of origin [4–6].
Today, critical functions of the lysosome in cancer cell biology as well as differences in cancer cell
lysosomes versus normal lysosomes are widely recognized. How exactly lysosomes contribute to
tumorigenesis and cancer progression is, however, still being uncovered [1,7].
Besides the lysosome-cancer link, there are also many established connections between cancer
and ion channels, both ion channels on the plasma membrane and on intracellular membranes.
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The oncogenic intracellular ion channels comprise mitochondrial channels such as Kv1.3 (KCNA3),
IKCa (KCNN4), and TASK-3, among others, in addition to the intracellular chloride channel CLIC-4
or different TRP (transient receptor potential) channels, e.g., TRPM8 and TRPC1 (for excellent recent
reviews see e.g., [8,9]; for other TRP channels in relation to cancer see e.g., [10,11]). Very recently,
the calcium permeable, non-selective endolysosomal two-pore cation channels (TPCs) were found to
play a role in cancer cell migration and β1-integrin trafficking and recycling [12,13]. In the following,
we give an overview on the roles of lysosomes in cancer and the involvement of endolysosomal TRPML
channels and TPCs.
2. Cancer Cell Lysosomes
Lysosomes in cancer cells are different from normal lysosomes in several aspects. For example,
enhanced protease activity and release from cancer cell lysosomes into the extracellular space is
often observed and found to promote tumor progression [3,14–16]. Secretion of cathepsins into
the extracellular space seems to be facilitated by altered trafficking of lysosomes in cancer cells,
which results in a shift of localization from perinuclear to peripheral. By contrast, cytosolic release
of lysosomal enzymes has been demonstrated to trigger apoptosis and cell death, providing a
rational for cancer therapies aiming at the destabilization of the lysosomal membranes [17,18].
Cancer cells need plenty of nutrients to grow. This leads to lysosomal alterations in cancer
cells such as increased expression and altered trafficking of lysosomal enzymes, as mentioned
above. Similarly, alterations in the autophagic compartment are linked to carcinogenesis as well
as resistance to chemotherapy. For example, the signaling pathways that activate mammalian target
of rapamycin (mTOR) are altered in many human cancers [19]. mTOR is a key signaling regulator
of autophagy, and the inhibition of mTOR by e.g., rapamycin or nutrient deprivation, induces the
activation of autophagy [20,21]. mTOR is also a downstream effector of the PI3K-AKT pathway.
PI3K (phosphatidylinositol-4,5-bisphosphate-3-kinase), which regulates the maturation, size, and
content of the lysosomal compartment, shows increased activity in many cancers [22,23]. In particular,
the PI3K-AKT-mTOR cascade is frequently hyperactivated in cancer, and plays an integral role
in tumor growth and survival [24]. Furthermore, the phosphatase that negatively regulates PI3K,
the tumor suppressor PTEN (phosphatase and tensin homolog) is mutated, silenced, or deleted in a
number of tumor types including glioblastoma, lung carcinoma, melanoma, hepatocellular carcinoma,
and prostate cancer [19].
The activation of PI3K can occur through tyrosine kinase growth factor receptors such as epidermal
growth factor receptor (EGFR) and insulin-like growth factor-1 receptor (IGF-1R), cell adhesion
molecules such as integrins, G-protein-coupled receptors (GPCRs), and oncogenes such as Ras [25].
The receptors that function upstream of PI3K are often mutationally activated or overexpressed in
cancer. Interfering with lysosomal function by the inhibition of the vacuolar H+-ATPase, which is
essential for lysosomal acidification, was recently demonstrated to abrogate excessive EGFR and
Ras signaling in cancer cells, leading to reduced migration and proliferation [26,27]. These findings
underline the potential of cancer cell lysosomes as drug targets. Finally, the subcellular positioning
(e.g., peripheral versus perinuclear) and distribution of lysosomes seems to contribute to various
pathologies including cancer progression [28,29].
3. Cancer and Inflammation
Inflammation is considered to be a generic mechanism of innate immunity as compared to
adaptive immunity, which is specific for each pathogen. The process of acute inflammation is
initiated by resident immune cells already present in the involved tissue, mainly resident macrophages,
dendritic cells, Kupffer cells, and mast cells. Chronic inflammation is caused by a variety of factors,
including bacterial, viral, and parasitic infections, chemical irritants, and non-digestible particles.
That chronic inflammation can increase the risk of cancer and other diseases is now widely accepted.
Several pathologies illustrate this link, such as endometriosis, chronic prostatitis, chronic gastritis, or
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inflammatory bowel disease (IBD) [30]. In IBD, especially Crohn’s disease patients, increased numbers
of cells positive for interferon-γ (IFN-γ), which is a proinflammatory cytokine with multiple functions,
have been observed, possibly contributing to a chronic inflammatory setting [30,31]. If inflammation
persists, the risk for associated carcinogenesis is increased [32]. Cancer cells also use proinflammatory
chemokines and their receptors for invasion, migration, and metastasis [33]. On the other hand,
many cells of the immune system also contribute to immune surveillance of cancer and cancer
suppression [33]. How this critical balance between the positive and negative effects of inflammation
and immune response is maintained and how a negative shift in this balance is promoted in cancer
progression needs to be further elucidated.
In recent years more and more evidence has accumulated demonstrating that TRPML channels
and TPCs are expressed in cells of the immune system, in particular macrophages, mast cells, and
dendritic cells, and that they may regulate the production and secretion of inflammatory mediators but
also immune cell migration [34–36]. In addition, TRPMLs and TPCs have been found to be involved in
mTOR signaling, autophagy, and EGF/EGFR as well as integrin trafficking.
4. TPCs and Cancer
TPCs are found in early endosomes as well as late endosomes/lysosomes and are postulated to
participate in the regulation of intracellular trafficking and fusion processes.
Links between TPCs and cancer have been summarized in a recent review by
Parrington et al. (2015) [37]. In addition, Nguyen et al. [13] have recently shown that TPCs play
a crucial role in cancer cell migration and tumor cell dissemination, as silencing TPC1 and TPC2
with siRNA or pharmacological inhibition reduces the adhesion and migration of invasive tumor
cells and the formation of lung metastases in an in vivo mouse model. Endosomes and lysosomes
control integrin trafficking and recycling which is required for (cancer) cell migration [28,38,39]. The
inhibition of TPCs leads to an accumulation of β1-integrin in endocytic vesicles and to an impaired
lamellipodia formation, indicating that TPCs are significantly involved in integrin recycling and
directed migratory processes.
Knockout mice lacking TPC2 also show an increased intracellular accumulation of EGF/EGFR,
potentially resulting from a defect in EGF/EGFR trafficking to lysosomes and subsequent
degradation [40]. This disrupted degradation of EGF/EGFR could lead to prolonged EGFR signaling
in endosomes, which may impact cancer cell proliferation. In addition, EGFR recycling may be affected
or changes in EGFR signaling may impact the PI3K-AKT-mTOR cascade and thus tumor growth and
survival, as discussed above.
It was also shown recently that the blockade of TPCs inhibits VEGF-induced neoangiogenesis
(formation of new blood vessels) [41] and that VEGF-induced neoangiogenesis is mediated by NAADP
and TPC2-dependent calcium signaling [42]. Neoangiogenesis accompanies tissue regeneration and
healing, but is also crucial for tumor growth [42]. As Favia et al. [42] pointed out, the formation
of new vascular capillaries, e.g., in inflammatory or cancer processes, proceeds through a defined
sequence of steps as diverse as cell proliferation, migration, differentiation, and morphogenesis, all of
which involve control by VEGF-linked signaling cascades. Favia et al. [42] further showed that the
inhibition of signaling pathways involving VEGFR2, NAADP, TPC2, and Ca2+ release from acidic stores
significantly decreases the activation of the known VEGFR2 downstream targets ERK1/2 MAPK, JNK,
Akt, and eNOS, and blocks angiogenesis in both in vitro and in vivo models. Whether this is a major
mechanism by which the blockade of TPCs results in anticancer effects awaits further exploration.
Importantly, it was also found that TPCs directly interact with mTOR [43]. High ATP levels, such
as those found in nutrient-replete cells, are postulated [43] to enable mTOR to phosphorylate TPCs
and to thus maintain the channel in the closed state (Figure 1). The channel complex thus detects
nutrient status and becomes constitutively open upon nutrient removal and mTOR translocation
off the lysosomal membrane [43]. mTOR is an atypical serine/threonine kinase that is present in
two distinct complexes. mTOR complex 1 (mTORC1) has five components: mTOR, which is the
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catalytic subunit of the complex; regulatory-associated protein of mTOR (Raptor); mammalian lethal
with Sec13 protein 8 (mLST8, also known as GbL); proline rich AKT substrate 40 kDa (PRAS40);
and DEP-domain-containing mTOR-interacting protein (Deptor) [44]. The second complex, mTOR
complex 2 (mTORC2) comprises six different proteins, several of which are common to mTORC1 and
mTORC2: mTOR; rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-activated
protein kinase interacting protein (mSIN1); protein observed with Rictor-1 (Protor-1); mLST8;
and Deptor [44]. mTORC2 promotes cellular survival by activating AKT, regulates cytoskeletal
dynamics by activating PKCα, and controls ion transport and growth via SGK1 phosphorylation.
Figure 1. Endolysosomal cation channels and mTORC1. Shown is an illustration of the mechanisms
underlying TFEB and mTORC1 modulation by lysosomal calcium released through TRPML1 and the
physical association and functional regulation (inhibition) of TPC activity by mTORC1. Li et al. [45]
reported the TRPML1-dependent activation of CaM, which associates with mTOR and activates
mTORC1. mTORC1 phosphorylates TFEB. This is required for its interaction with 14-3-3 and the
prevention of TFEB nuclear translocation. Medina et al. [46] described a TRPML1-dependent activation
of calcineurin, which leads to the dephosphorylation of TFEB. TFEB then translocates to the nucleus to
start the transcription of CLEAR network genes [47,48]. Furthermore, mTORC1 activation can block
TPC activity and thus calcium/sodium flux from lysosomes (Cang et al. [43]). Sphingosine-induced
activation of TPC1 leads to the translocation of TFEB to the nucleus after lysosomal calcium release
(Höglinger et al. [49]).
Knockdown of Raptor, but not Rictor, reduced the ATP inhibition of TPCs, suggesting that the
ATP sensitivity of TPCs is conferred by the mTORC1 complex [43].
It is well established that aberrant mTOR signaling is involved in many disease states including
cancer, cardiovascular disease, and diabetes. How the interaction with and the inhibition by mTOR
might affect possible roles of TPCs in cancer development and progression remains to be elucidated.
5. TRPMLs and Cancer
In contrast to TPCs, the ATP-insensitive endolysosomal TRPML channels were found to have
little or no detectable association with mTOR [43]. Nevertheless, TRPML1 has recently been shown to
be involved in mTOR signaling [45,46,50]. The blockade of lysosomal calcium release due to lysosomal
lipid accumulation is known to inhibit mTOR signaling. The mechanism by which lysosomal calcium
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regulates mTOR remained undefined, until Li et al. [45] reported that proper lysosomal calcium release
through TRPML1 is required for mTORC1 activation. Consequently, TRPML1 depletion inhibits
mTORC1 activity, while the overexpression or pharmacologic activation of TRPML1 has the opposite
effect. Lysosomal calcium activates mTORC1 by inducing the association of calmodulin (CaM) with
mTOR (Figure 1). Blocking the interaction between mTOR and CaM by antagonists of CaM significantly
inhibits mTORC1 activity. Moreover, CaM is capable of stimulating the kinase activity of mTORC1 in a
calcium-dependent manner in vitro. The results provided by Li et al. [45] revealed that mTOR is a new
type of CaM-dependent kinase, and TRPML1, lysosomal calcium, and CaM play essential regulatory
roles in the mTORC1 signaling pathway [45].
Medina et al. [46] found that lysosomal calcium release through TRPML1 activates calcineurin,
which binds and dephosphorylates transcription factor EB (TFEB), thus promoting its nuclear
translocation. TFEB is a master regulator of lysosomal and autophagic function and, intriguingly,
the induction of autophagy and lysosomal biogenesis through TFEB requires TRPML1-mediated
calcineurin activation (Figure 1). Altered TFEB expression and/or activity has recently been
associated with pancreatic cancer cell proliferation [51] and non-small cell lung cancer motility [52],
and Calcagnì et al. recently showed that kidney-specific TFEB overexpression in transgenic mice
resulted in renal clear cells, multi-layered basement membranes, severe cystic pathology, and ultimately
papillary carcinomas with hepatic metastases [53].
As described by Roczniak-Ferguson et al. [54] TFEB is recruited to lysosomes via an interaction
with mTORC1, and the mTORC1-dependent phosphorylation of TFEB is required for its interaction
with 14-3-3 and the prevention of TFEB nuclear translocation. The exact mechanism(s) governing
the TRPML1-mediated regulation of mTOR and TFEB signaling, as described by Li et al. [45]
and Medina et al. [46], need further investigation. In this context, it is also of interest that TPC1
mediated endolysosomal calcium release by sphingosine (SPH), which has been postulated by
Höglinger et al. [49] to be important for the translocation of TFEB to the nucleus [49] (Figure 1).
These findings illustrate that the lysosome is not only important for degradation and
trafficking/recycling processes but is also discussed as a signaling hub affecting different transcription
factors, in particular TFEB, with an important impact on metabolism and cancer [55,56].
Following the hypothesis that TRPMLs and TPCs play a role in mTOR signaling by affecting
MITF/TFEB activity and thus the CLEAR gene network (coordinated lysosomal expression and
regulation gene network; [47,48]), a more detailed analysis of TFEB activation (i.e., translocation
into the nucleus) and the transcription of TFEB target genes in WT versus TRPML/TPC KD/KO
cancer cells is warranted. Beyond that, other aspects of TRPML channel activation such as the impact
of TRPML1 on lysosomal exocytosis [57–59] or lysosome motility [60] need to be studied in more
detail in the context of cancer. Namely, the inhibition of lysosomal exocytosis has been recently
demonstrated to reverse invasiveness and chemoresistance in aggressive sarcoma cells, revealing that
lysosomal exocytosis plays a primary role in tumor progression and chemoresistance [61]. Furthermore,
TRPML2 knockdown has recently been shown to inhibit the viability, to alter the cell cycle, to reduce the
proliferation, and to induce apoptotic cell death in glioma cell lines. The high TRPML2 expression levels
in glioma cells resulted in increased survival and proliferation signaling, suggesting a pro-tumorigenic
role played by TRPML2 in glioma progression [62].
In summary, it is evident that TPCs and TRPMLs are functionally relevant at the key control
points of intracellular trafficking and transport, affecting cell proliferation, autophagy, and survival.
This is specifically highlighted by their interference with mTOR and TFEB function and signaling.
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